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After the ﬁrst description by the French neurologist Georges
Gilles de la Tourette in 1885 [3], Tourette Syndrome (TS)
has fascinated many clinicians and researchers over the
decades. But to date there are relatively few studies on tic
disorders (PubMed search 29 January 2011, n = 1,283) and
TS (n = 3,762) compared to other neurodevelopmental
disorders with onset in childhood such as attention/deﬁcit-
hyperactivity disorder (ADHD, n = 18,572) or obsessive–
compulsive disorders (OCD, n = 12,558). Thus it is not
surprising that the evidence base on etiology, assessment,
andtreatmentisstilllimited,althoughthereisahighlevelof
clinical experience, particularly in specialized centers.
One of the many reasons for the small base of high-
quality evidence in diagnosing and treating children and
adolescents with TS could be seen in the fact that it has
only recently become evident that TS and other tic disor-
ders are not rare at all [10] and may negatively impact the
quality of life of those affected. This underestimation, in
combination with a high rate of relatively mild cases and
an often favorable course, with good chance of spontane-
ous remission, might explain why the necessity for study-
ing TS has been neglected.
The progress of methodologically sound research in the
ﬁeld of TS has been further hampered by the fact that tics
show an extremely high variability over time in frequency,
severity, complexity, localization and chronicity [5], which
requireslong-termobservationsinlargesamples.Inaddition
itisnotstraightforwardwhichspecialtyshoulddealwithTS,
a cause for further fragmentation. The core symptoms of TS
(i.e., tics) could be seen as a neurologic hyperkinetic
movement disorder. However, its neurodevelopmental
character and the high rate of different comorbidities, e.g.
attention-deﬁcit/hyperactivity disorder (ADHD) or obses-
sive–compulsive disorders (OCD) suggest its allocation to
child and adolescent psychiatry. Although this has triggered
a lively interdisciplinary dialogue it might, on the other
hand, be one further cause for the lack of strong and large
(inter)national research projects in this ﬁeld.
To overcome this unsatisfactory situation the European
Society for the Study of Tourette Syndrome (ESSTS) has
been established (originally in 2000 in Copenhagen by
Prof. Mary Robertson and others, but re-established in
2008 in Bari after a prolonged silent period). Membership
is open to European clinicians and researchers who have an
interest in TS. The aims of ESSTS are:
• to enhance understanding of the causes of TS,
• to ﬁnd effective treatments for TS,
• to share good practice, and
• to stimulate European collaboration in research.
These guidelines represent the collective view of expert clinicians in
the area and are not intended to be rules and conditions since rules
and conditions in different countries may vary, such as drug licensing
or the availability of therapists.
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DOI 10.1007/s00787-011-0165-5Therefore we as ESSTS members have decided at our
annual meeting in Leiden 2008 to join the forces by
developing the ﬁrst version of European clinical guidelines
for TS and other tic disorders. This seemed particularly
relevant as ESSTS contains a lot of clinical and research
expertise on TS from different disciplines across Europe,
while the only three existing Cochrane Reviews on the
treatment of tics in TS are all limited to pharmacological
treatment [1, 8, 9] and came to the same conclusion, i.e.
that the evidence for efﬁcacy and safety of the studied
drugs does not allow ﬁrm recommendations. This unde-
sirable situation is also reﬂected by the fact that to the best
of our knowledge in Europe there are currently only
national guidelines in Germany [6, 11]. In addition, while
there have been several excellent reviews on the assess-
ment and treatment of TS, these have typically failed to use
systematic criteria of study selection [2, 4, 7].
Despite existing wide variations from even tertiary
center to tertiary center across Europe, we are proud to
present the ﬁrst version of European clinical guidelines for
TS and other tic disorders. We have set up writing groups
working on thorough literature review for existing evi-
dence base, adding clinical experience and expertise
including intensive and fruitful discussions within ESTSS
during the last 2 years. These guidelines hopefully will
help clinicians to offer the best clinical service to affected
children, adolescents, and adults and inspire clinical
researchers as well as politicians to no longer overlook the
high burden of tic disorders.
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